https://lungsummit.org/articles/egfr-amplification-at-baseline-marks-shorter-time-on-first-line-osimertinib-in-exon-19-deletions-but-not-l858r/ 2026-08-09T05:11:06+00:00 https://lungsummit.org/articles/orchard-final-data-osimertinib-plus-gefitinib-gives-modest-benefit-in-egfr-c797x-and-the-authors-advise-against-further-study/ 2026-08-09T05:11:04+00:00 https://lungsummit.org/articles/radiation-plus-durvalumab-without-chemotherapy-cleared-its-survival-target-in-frail-la-nsclc-patients/ 2026-08-07T16:32:10+00:00 https://lungsummit.org/articles/evoke-01-biomarker-analysis-trop-2-staining-did-not-pick-out-who-does-better-on-sacituzumab-govitecan-than-docetaxel/ 2026-08-07T16:28:43+00:00 https://lungsummit.org/articles/trastuzumab-deruxtecan-in-her2-mutant-nsclc-evidence-from-the-largest-real-world-cohort-to-date/ 2026-08-05T14:13:25+00:00 https://lungsummit.org/articles/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung-cancer/ 2026-08-05T14:13:04+00:00 https://lungsummit.org/articles/sac-tmt-plus-pembrolizumab-improves-pfs-in-pd-l1-negative-nsclc/ 2026-08-05T14:13:02+00:00 https://lungsummit.org/articles/proton-pump-inhibitors-and-antibiotics-linked-to-reduced-durvalumab-benefit-in-unresectable-stage-iii-nsclc/ 2026-08-05T14:12:59+00:00 https://lungsummit.org/articles/antibody-drug-conjugates-across-solid-tumours-an-etop-ibcsg-expert-group-sets-the-research-priorities/ 2026-08-05T14:12:56+00:00 https://lungsummit.org/articles/roche-reports-positive-phase-3-results-for-divarasib-in-previously-treated-kras-g12c-nsclc/ 2026-08-05T14:12:54+00:00 https://lungsummit.org/articles/astrazeneca-reports-five-year-adjuvant-osimertinib-follow-up-data-in-early-stage-egfr-mutated-nsclc/ 2026-08-05T14:12:51+00:00